Inhibition of tumor growth and angiogenesis by soluble EphB4

Neoplasia

Volumn 6, Issue 3, 2004, Pages 248-257

  Martiny Baron, Georg ^a   Korff, Thomas ^a   Schaffner, Florence ^a   Esser, Norbert ^a   Eggstein, Stefan ^a   Marmé, Dieter ^a   Augustin, Hellmut G ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Angiogenesis; Endothelial cells; EphB4; EphrinB2; Tumor

Indexed keywords

EPHRIN; EPHRIN B2; EPHRIN B4; EPHRIN RECEPTOR; LIGAND; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CONTACT; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA CELL; MONOLAYER CULTURE; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 2442706421     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.3457     Document Type: Article

References (42)

1. Klein R (2001). Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol 13, 196-203.
2. Kullander K and Klein R (2002). Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3, 475-486.
3. Schmucker D and Zipursky SL (2001). Signaling downstream of Eph receptors and ephrin ligands. Cell 105, 701-704.
4. Bruckner K, Pasquale EB, and Klein R (1997). Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275, 1640-1643.
5. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, and Pawson T (1996). Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 383, 722-725.
6. Orioli D and Klein R (1997). The Eph receptor family: axonal guidance by contact repulsion. Trends Genet 13, 354-359.
7. Wang HU, Chen ZF, and Anderson DJ (1998). Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753.
8. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, and Klein R (1999). Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13, 295-306.
9. Adams RH (2002). Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13, 55-60.
10. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, and Yancopoulos GD (2001). Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth muscle cells. Dev Biol 230, 151-160.
11. Shin D, Garcia-Cardena G, Hayashi SI, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA, and Anderson DJ (2001). Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 230, 139-150.
12. Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, and Klein R (2001). The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 104, 57-69.
13. Füller T, Korff T, Kilian A, Dandekar G, and Augustin HG (2003). Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 116, 2461-2470.
14. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, and Clevers H (2002). Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111, 251-263.
15. Dodelet VC and Pasquale EB (2000). Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19, 5614-5619.
16. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, and Ellis LM (2002). Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94, 934-939.
17. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, and Pasquale EB (2000). The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043-6052.
18. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, and Kinch MS (2001). EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61, 2301-2306.
19. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, and Chen J (2002). Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011-7026.
20. Carles-Kinch K, Kilpatrick KE, Stewart JC, and Kinch MS (2002). Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62, 2840-2847.
21. Nakamoto M and Bergemann AD (2002). Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59, 58-67.
22. Chen E, Xia G, Kundra A, Smith DL, Masood R, and Gill P (2003). EphB4/ephrinB2 expression by malignant mesothelioma as a potential therapeutic target. Proc Am Assoc Cancer Res 44, 475.
23. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, and Hardingham JE (2001). Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2, 15.
24. Vogt T, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, Landthaler M, and McClelland M (1998). Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 4, 791-797.
25. Takai N, Miyazaki T, Fujisawa K, Nasu K, and Miyakawa I (2001). Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep 8, 567-573.
26. Nikolova Z, Djonov V, Zuercher G, Andres AC, and Ziemiecki A (1998). Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrinB2 during mammary gland morphogenesis. J Cell Sci 111, 2741-2751.
27. Tang XX, Evans AE, Zhao H, Cnaan A, London W, Cohn SL, Brodeur GM, and Ikegaki N (1999). High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 5, 1491-1496.
28. Tang XX, Zhao H, Robinson ME, Cohen B, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, and Ikegaki N (2000). Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci USA 97, 10936-10941.
29. Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, and Marme D (2002). PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62, 4015-4022.
30. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, and Martiny-Baron G (1999). Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59, 3185-3191.
31. Korff T and Augustin HG (1998). Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143, 1341-1352.
32. Korff T and Augustin HG (1999). Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112, 3249-3258.
33. Hamada K, Oike Y, Ito Y, Maekawa H, Miyata K, Shimomura T, and Suda T (2003). Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 23, 190-197.
34. Huynh-Do U, Vindis C, Liu H, Cerretti DP, McGrew JT, Enriquez M, Chen J, and Daniel TO (2002). Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci 115, 3073-3081.
35. Ferrara N (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29, 10-14.
36. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, and Bohlen P (1998). Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17, 155-161.
37. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, and Strawn LM (1996). Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56, 1615-1620.
38. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, and Stahl N (2003). Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9, 47-52.
39. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, and Rudge JS (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99, 11393-11398.
40. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, and Marme D (1997). Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 57, 5421-5425.
41. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, and Kinzler KW (2000). Genes expressed in human tumor endothelium. Science 289, 1197-1202.
42. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otsuki Y, Kobayashi T, Konno H, Hanai H, and Sugimura H (2002). Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 128, 343-348.